Arthrosi Therapeutics

Executive Summary

Arthrosi Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, founded in 2018, focused on developing novel small molecule therapies for gout and inflammatory diseases. Gout is a prevalent and debilitating condition caused by elevated uric acid levels, leading to painful flares and joint damage. Despite available treatments, significant unmet need remains, particularly for patients with renal impairment who cannot tolerate standard therapies. Arthrosi's lead candidate aims to address this gap by effectively lowering uric acid, reducing flares, and resolving tophi, with a favorable safety profile in renally impaired patients.

Upcoming Catalysts (preview)

• H2 2026Phase 2b/3 Topline Data for Lead Candidate in Gout50% success
• H1 2027Regulatory Update or End-of-Phase 2 Meeting with FDA70% success
• 2026Potential Partnership or Licensing Deal for Greater China or Other Territories40% success